IPSEN (OTCMKTS:IPSEY) Sets New 12-Month High – Still a Buy?
by Jessica Moore · The Cerbat GemShares of IPSEN (OTCMKTS:IPSEY – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $47.81 and last traded at $47.81, with a volume of 158 shares. The stock had previously closed at $44.97.
Wall Street Analyst Weigh In
IPSEY has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research report on Tuesday, February 17th. BNP Paribas Exane cut shares of IPSEN to an “underperform” rating in a research note on Wednesday, November 26th. Finally, UBS Group downgraded shares of IPSEN from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 8th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.
View Our Latest Report on IPSEY
IPSEN Stock Performance
The business has a 50 day moving average price of $39.98 and a 200-day moving average price of $36.54.
IPSEN Company Profile
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).